Last updated: August 1, 2026
Meticorten is the former brand name for prednisone, a synthetic glucocorticoid used for inflammatory, allergic, autoimmune and hematologic conditions. The brand has no meaningful current clinical-development program, no identifiable branded market share in the United States and no active exclusivity position comparable to a modern specialty drug. Commercial activity is concentrated in low-cost generic prednisone tablets and oral solutions. Clinical-trial activity relates to prednisone as an active ingredient, not to Meticorten as a marketed brand.
What is Meticorten and what drug does it contain?
Meticorten contains prednisone, an orally administered corticosteroid. Prednisone is converted in the liver to prednisolone, the pharmacologically active metabolite. The drug suppresses inflammation and immune activity through glucocorticoid-receptor signaling.
| Attribute |
Meticorten |
| Active ingredient |
Prednisone |
| Drug class |
Systemic glucocorticoid |
| Route |
Oral |
| Historical dosage forms |
Tablets; formulations varied by market |
| Primary uses |
Rheumatic, allergic, dermatologic, respiratory, hematologic and other inflammatory disorders |
| Original innovator |
Schering Corporation, historically |
| Current U.S. status |
Historical brand; generic prednisone products dominate |
| Biosimilar status |
Not applicable |
| Commercial maturity |
Very mature, multi-source generic market |
Prednisone is generally prescribed for short courses, tapering regimens or chronic low-dose therapy. Long-term use can cause adrenal suppression, osteoporosis, hyperglycemia, infection risk, hypertension, cataracts and other corticosteroid-related complications. The FDA labeling for prednisone emphasizes dose individualization and gradual withdrawal after prolonged treatment.[1]
What is the FDA regulatory status of Meticorten?
The relevant regulatory status is the status of prednisone products rather than an active Meticorten franchise. FDA-approved prednisone products are available from multiple generic manufacturers in tablet strengths that commonly include 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg and 50 mg, although specific strengths and suppliers can change.
Meticorten is not a current U.S. growth product. Historical branded approvals and product listings do not create meaningful present-day exclusivity. The FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, known as the Orange Book, lists approved prednisone products and therapeutic-equivalence information for generic versions.[2]
Is Meticorten still marketed in the United States?
Meticorten is not a significant current U.S. commercial brand. U.S. prescriptions are generally dispensed as generic prednisone. Pharmacy availability depends on manufacturer inventory, wholesaler supply and dosage strength.
The brand may remain recognized in certain international markets or historical medical literature, but that does not establish an active U.S. commercial business. Country-specific registration and marketing status must be assessed separately because the Meticorten name has had different commercial histories across jurisdictions.
Are there clinical trials for Meticorten?
There is no major active clinical-development program for Meticorten as a branded product. ClinicalTrials.gov contains studies involving prednisone, prednisolone or corticosteroid regimens, but these studies generally evaluate the drug as an established standard therapy or background treatment rather than develop Meticorten as a new product.[3]
What types of prednisone clinical trials remain active?
Current and recent prednisone-related studies generally fall into the following categories:
| Trial category |
Role of prednisone |
Commercial significance |
| Autoimmune disease |
Active treatment, comparator or tapering regimen |
Low for the brand; supports established clinical use |
| Hematologic disease |
Combination therapy or supportive treatment |
Low to moderate for generic suppliers |
| Oncology |
Component of multi-drug regimens, including corticosteroid-containing protocols |
No standalone brand opportunity |
| Transplant medicine |
Immunosuppression or steroid withdrawal studies |
Supports clinical utilization |
| Respiratory disease |
Short-course anti-inflammatory therapy |
High prescription volume, low pricing power |
| Pediatric inflammatory disease |
Treatment or steroid-sparing comparison |
Limited commercial effect |
| Adrenal and endocrine conditions |
Replacement or tapering protocols |
Established-use market |
Prednisone clinical research does not normally generate new product exclusivity because the active ingredient is old, the dosage forms are conventional and the primary clinical questions concern treatment strategy, duration, combination therapy or disease management.
Does prednisone have new-drug clinical-trial potential?
A new prednisone product could generate development value if it introduced a differentiated delivery system, reduced systemic exposure, improved adherence or addressed a specific pediatric, endocrine or inflammatory indication. A conventional immediate-release prednisone tablet would face a weak investment case because generic equivalents are widely available and the active ingredient has extensive clinical history.
Potential development areas include modified-release products, localized delivery, dose-sparing combinations and formulations designed to reduce gastrointestinal or systemic adverse effects. These concepts would require product-specific clinical evidence and would not revive the Meticorten brand automatically.
What patents protect Meticorten or prednisone?
No commercially relevant active U.S. patent estate is associated with the historical Meticorten brand. Prednisone is an established small-molecule drug, and the core composition-of-matter protection expired long ago. Generic manufacturers compete through abbreviated new drug applications, manufacturing scale, supply reliability and, in some cases, formulation or packaging differences.
| IP category |
Current relevance to Meticorten |
| Core prednisone compound patent |
Expired |
| Historical Meticorten brand patents |
No material current exclusivity identified |
| Conventional tablet patents |
Generally expired or commercially weak |
| Method-of-use patents |
Possible for later treatment concepts, but not a general Meticorten barrier |
| Manufacturing patents |
May protect specific processes, but do not block generic prednisone broadly |
| Formulation patents |
Relevant only to differentiated products |
| Trademark rights |
May exist by country, but do not prevent generic prednisone sales |
A patent on a specific formulation, combination or delivery platform would protect that product, not prednisone as a molecule. Patent analysis therefore must distinguish historical Meticorten rights from later patents covering prednisone combinations or specialized dosage forms.
When did Meticorten lose exclusivity?
Meticorten lost meaningful exclusivity decades ago. The product belongs to the pre-modern generic era, and prednisone has long been supplied by multiple manufacturers. There is no current FDA exclusivity period that would delay approval of ordinary generic prednisone tablets.
The practical loss of exclusivity occurred through three mechanisms:
- Expiration of historical compound and product rights.
- FDA approval of therapeutically equivalent generic prednisone products.
- Substitution by pharmacies and payers based on low generic acquisition costs.
No current commercial forecast should treat Meticorten as an exclusivity-protected product.
What is the Orange Book status of Meticorten?
The Orange Book is relevant to approved prednisone products and their therapeutic-equivalence evaluations. It is not a source of current commercial exclusivity for the historical Meticorten brand.
Generic prednisone products may carry approved product listings without having any remaining patent or regulatory exclusivity. Orange Book inclusion indicates FDA approval status and, where applicable, therapeutic equivalence. It does not imply that the original brand retains market protection.[2]
Are there Paragraph IV challenges for Meticorten?
Paragraph IV litigation is not a current commercial issue for the historical Meticorten brand. Paragraph IV certifications apply when an abbreviated new drug application applicant challenges listed patents associated with a reference-listed drug. Because conventional prednisone products are long-established and broadly genericized, new Paragraph IV activity would not normally be expected for ordinary prednisone tablets.
A Paragraph IV dispute could arise around a later proprietary prednisone formulation, combination product or delivery system. That would concern the later product’s listed patents rather than the historical Meticorten brand.
What generic entry risks exist for Meticorten?
Generic entry risk is effectively realized rather than prospective. Prednisone is already a multi-source generic product.
Current competitive risks
The main risks are:
- Price erosion from multiple approved manufacturers.
- Pharmacy substitution of branded or imported products.
- Hospital and government purchasing pressure.
- Supply interruptions caused by API sourcing or manufacturing concentration.
- Competition among tablet strengths and dosage-form suppliers.
- Limited physician incentive to prescribe a historical brand.
The main commercial differentiator is supply reliability. A manufacturer with dependable production, broad strength coverage and stable wholesaler relationships can maintain volume, but pricing power remains limited.
How does Meticorten compare with competing corticosteroids?
Meticorten competes at the active-ingredient level with generic prednisone, not with other brands. Therapeutic alternatives include prednisolone, methylprednisolone, dexamethasone and hydrocortisone.
| Drug |
Relative commercial position |
Common market rationale |
| Prednisone |
Mature, low-cost generic |
Broad oral use and extensive clinical familiarity |
| Prednisolone |
Mature generic |
Often preferred in liquid formulations or selected pediatric and hepatic settings |
| Methylprednisolone |
Mature generic |
Alternative potency and dosing profile |
| Dexamethasone |
Mature generic |
High potency, longer duration and broad hospital use |
| Hydrocortisone |
Mature generic |
Replacement therapy and acute-care applications |
Prednisone remains commercially relevant because of prescribing familiarity and broad indications. Its market is volume-driven rather than innovation-driven.
What is the market outlook for Meticorten and prednisone?
The Meticorten brand has little standalone market potential. The prednisone market should remain stable in unit demand but constrained in revenue growth.
Market projection
| Period |
Expected market direction |
Main drivers |
| 2025-2027 |
Stable to modest unit growth |
Chronic inflammatory disease, respiratory use and aging populations |
| 2028-2030 |
Stable volume; continued price pressure |
Generic competition and payer control |
| 2031 onward |
Mature, low-growth market |
Established prescribing, limited innovation and substitution |
A realistic base case is low-single-digit annual unit growth with flat-to-low-single-digit revenue growth, depending on geography and dosage form. Revenue growth is likely to trail prescription growth because generic price competition offsets volume gains.
Public market reports often combine prednisone with broader corticosteroid or systemic anti-inflammatory categories. Those estimates should not be interpreted as Meticorten revenue. Meticorten-specific revenue is unlikely to be separately reported by major public companies because the brand is not a significant current global franchise.
What factors could increase prednisone market value?
Growth could come from:
- Higher diagnosis rates for autoimmune and inflammatory disorders.
- Increased use in oncology and hematology protocols.
- Expansion of low-cost treatment in emerging markets.
- Demand for pediatric liquid or easier-to-administer formulations.
- Supply consolidation that temporarily raises generic prices.
- New proprietary delivery systems using prednisone as the active ingredient.
These factors would increase the value of prednisone supply or a differentiated formulation, not necessarily the historical Meticorten brand.
How strong is the patent estate for Meticorten?
The patent estate is weak for conventional Meticorten or immediate-release prednisone tablets. The product has no meaningful molecule-level barrier, no active brand exclusivity and no biosimilar protection because prednisone is a chemically synthesized small molecule.
Patent strength would be higher only for a new product with:
- A novel modified-release profile.
- A proprietary combination.
- A disease-specific delivery mechanism.
- A validated reduction in systemic corticosteroid toxicity.
- Manufacturing claims that are difficult to design around.
Even in those cases, the commercial opportunity would depend on clinical differentiation, payer coverage and the ability to obtain a premium over generic prednisone.
What patent litigation affects Meticorten?
No major current patent litigation is associated with the historical Meticorten brand or ordinary generic prednisone tablets. The absence of litigation reflects the age of the product and the lack of a commercially meaningful patent barrier.
Future disputes could involve proprietary corticosteroid formulations, manufacturing processes or combination therapies. Those disputes would have limited relevance to standard prednisone supply unless the claims covered a broad and enforceable manufacturing route.
What licensing deals involve Meticorten?
No major current licensing transaction involving Meticorten is publicly material to the market. Historical brand ownership and distribution arrangements may have existed in individual countries, but the product’s current value is not based on an active licensing platform.
Licensing value would be more likely to arise from:
- A novel prednisone delivery system.
- A regional registration with limited generic competition.
- A supply agreement for difficult-to-source strengths.
- A combination product with a proprietary active ingredient.
- An acquisition of a broader corticosteroid portfolio.
What are the likely generic launch scenarios?
For standard prednisone tablets, generic launch risk is already fully realized. The relevant scenarios concern future products rather than Meticorten itself.
Base case
Generic prednisone remains widely available, with stable demand and ongoing price competition. No branded relaunch achieves durable premium pricing.
Upside case
A manufacturer introduces a differentiated formulation that improves adherence, reduces dosing frequency or targets a high-value patient population. The product obtains regulatory protection and captures a limited specialty segment.
Downside case
API disruption, manufacturing failures or product discontinuations cause temporary shortages in selected strengths. Prices rise temporarily, but new suppliers enter once the shortage creates an economic incentive.
Does prednisone face biosimilar competition?
No. Biosimilars apply to biological products. Prednisone is a synthetic small molecule and competes through conventional generic-drug pathways, primarily abbreviated new drug applications in the United States. The competitive issue is generic substitution, not biosimilar interchangeability.
Key Takeaways
- Meticorten is a historical prednisone brand, not an active high-value development asset.
- No meaningful current clinical-trial program is associated with Meticorten as a brand.
- Prednisone clinical studies continue, but mostly evaluate established treatment strategies.
- Conventional prednisone patents and exclusivity rights expired long ago.
- The U.S. market is dominated by generic prednisone products.
- Paragraph IV litigation is not a material current issue for ordinary prednisone tablets.
- The commercial market is mature, price-sensitive and likely to show stable unit demand with limited revenue growth.
- New value would require a proprietary formulation, delivery system, combination or manufacturing advantage.
- Biosimilar risk is not applicable; generic substitution is the relevant competitive risk.
- Meticorten-specific revenue is unlikely to be separately material in current public market reporting.
FAQs
Is Meticorten the same as prednisone?
Yes. Meticorten is a historical brand name for prednisone, although product availability and registration status vary by country.
Is Meticorten still available by prescription?
Availability depends on jurisdiction. In the United States, patients generally receive generic prednisone rather than Meticorten-branded product.
Does Meticorten have patent protection?
No commercially meaningful current patent protection is associated with conventional Meticorten or immediate-release prednisone tablets.
Can a company launch a generic version of Meticorten?
A company can market an approved generic prednisone product if it satisfies the applicable regulatory requirements. It generally does not need to recreate the historical Meticorten brand.
Is prednisone a biologic drug?
No. Prednisone is a synthetic small molecule. Generic-drug approval rules apply, not biosimilar regulations.
References
-
U.S. Food and Drug Administration. (n.d.). Prednisone prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
National Library of Medicine. (n.d.). ClinicalTrials.gov search results for prednisone. https://clinicaltrials.gov/search?term=prednisone
